PSTX - Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
2024-03-17 00:40:48 ET
Summary
- Additional results from the phase 1 study, using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory multiple myeloma, are expected at AACR on April 8th of 2024; Other data 2nd half of 2024.
- The global multiple myeloma market size is projected to reach $31 billion by 2026.
- Allogenic off-the-shelf CAR-T technology has already garnered strategic investment interest from Astellas and a collaboration agreement with Roche.
- Other advancements of the company's technology would be deploying a dual antigen targeting approach with P-CD19CD20-ALLO1, targeting solid tumors with P-MUC1C-ALLO1, increased dosing of lymphodepletion, piggyBac cargo, and higher CAR-T dosing.
Poseida Therapeutics ( PSTX ) is expected to release results from the phase 1 study using P-BCMA-ALLO1 for the treatment of patients with relapsed or refractory multiple myeloma [r/r MM] on April 8th, 2024 12:30 p.m. PT at the American Association for Cancer Research [AACR] Annual Meeting in San Diego. Why should investors care? For starters, if this catalyst is positive, it could cause the stock price to trade higher. Positive data was already released at the ASH 2023 medical conference using P-BCMA-ALLO1 to treat this relapsed/refractory patient population. Secondly, additional data released there could further establish proof-of-concept in using this allogenic off-the shelf CAR-T approach to treat hematological malignancies. Another factor to consider would be that it would move the treatment paradigm forward in the CAR-T space....
Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement